Guo, Z., Lu, X., Yang, F., Qin, L., Yang, N., Wu, J., & Wang, H. (2022). Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: An efficacy and safety analysis. BMC.
Cytowanie według stylu Chicago (wyd. 17)Guo, Zhuifeng, Xuwei Lu, Fan Yang, Liang Qin, Ning Yang, Jiawen Wu, i Hang Wang. Docetaxel Chemotherapy Plus Androgen-deprivation Therapy in High-volume Disease Metastatic Hormone-sensitive Prostate Cancer in Chinese Patients: An Efficacy and Safety Analysis. BMC, 2022.
Cytowanie według stylu MLA (wyd. 9)Guo, Zhuifeng, et al. Docetaxel Chemotherapy Plus Androgen-deprivation Therapy in High-volume Disease Metastatic Hormone-sensitive Prostate Cancer in Chinese Patients: An Efficacy and Safety Analysis. BMC, 2022.